KRAS and BRAF Mutations, Histopathological Features and Tumor Budding in Bangladeshi Patients with Colorectal Carcinoma
Abstract
Background: KRAS and BRAF mutations predict resistance to antibodies against the epidermal growth factor receptor (EGFR) in colorectal carcinoma (CRC), but Bangladeshi data are scarce. This study determined KRAS and BRAF mutation frequencies in resected CRC and their associations with clinicopathological features and tumor budding. Methods: This cross-sectional study included 40 consecutive resected colorectal adenocarcinomas at Bangabandhu Sheikh Mujib Medical University, Dhaka, between September 2014 and August 2016. Tumor and matched normal mucosa were screened for KRAS and BRAF mutations by high resolution melting analysis. Histopathology and tumor budding were assessed on hematoxylin and eosin sections. Associations were tested with chi square, Fisher’s exact and unpaired t tests. Results: KRAS mutation was found in 14 tumors (35.0%), BRAF mutation in 5 (12.5%), and both in 2 (5.0%). Lymphovascular invasion was absent in all KRAS mutant tumors but present in 7 of 26 (26.9%) wild type tumors (p = 0.035). Age, sex, nodal status and stage did not differ by KRAS status. All cecal tumors and all tumors over 10 cm were KRAS mutant. All BRAF mutant tumors were moderately differentiated rectal adenocarcinomas. KRAS mutation occurred in 61.5% of high grade, 20.0% of low grade and 22.7% of nonbudding tumors (p = 0.051), and BRAF mutation in 23.1%, 20.0% and 4.5%, respectively (p = 0.239). Conclusions: KRAS mutation affected over one third of this cohort, supporting routine genotyping before EGFR targeted therapy. BRAF and concurrent mutation calls need sequencing confirmation. The borderline excess of KRAS mutation in high grade budding tumors warrants larger studies.